Screening for liver X receptor modulators: Where are we and for what use?
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Liver X receptors (LXRs) are members of the nuclear receptor superfamily that are canonically activated by oxidized derivatives of cholesterol. Since the mid‐90s, numerous groups have identified LXRs as endocrine receptors that are involved in the regulation of various physiological functions. As a result, when their expression is genetically modified in mice, phenotypic analyses reveal endocrine disorders ranging from infertility to diabetes and obesity, nervous system pathologies such Alzheimer's or Parkinson's disease, immunological disturbances, inflammatory response, and enhancement of tumour development. Based on such findings, it appears that LXRs could constitute good pharmacological targets to prevent and/or to treat these diseases. This review discusses the various aspects of LXR drug discovery, from the tools available for the screening of potential LXR modulators to the current situational analysis of the drugs in development. LINKED ARTICLES: This article is part of a themed issue on Oxysterols, Lifelong Health and Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.16/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Daina, A., Michielin, O., & Zoete, V. (2017) · Scientific Reports · doi:10.1038/srep42717 · Cited by 18,367
ZINC 15 – Ligand Discovery for Everyone
Sterling, T., & Irwin, J. J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00559 · Cited by 3,224
The coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233 · cited 1×
“…and histone acetyltransferase p300 (E1A-p300) are considered keys to promote the transcriptional activation of the target genes in a process called transactivation (Albers et al., 2006; Glass & Rosenfeld, 2000; Herzog et al., 2007; Huuskonen, Fielding, & Fielding, 2004; Lee, Lee, Lee, & Lee, 2008).”
BackgroundReciprocal regulation of inflammation and lipid metabolism by liver X receptors
Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J., & Tontonoz, P. (2003) · Nature Medicine · doi:10.1038/nm820 · Cited by 1,158
Liver X receptors as integrators of metabolic and inflammatory signaling
Zelcer, N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27883 · Cited by 978 · cited 1×
“…with LXR agonists interfered with the transcriptional up-regulation of inflammatory genes (IL-6, IL-1β, TNFα, COX-2, MMP9, and iNOS) induced by the activity of transcription factors such as NF-κB and AP-1 (Joseph, Castrillo, Laffitte, Mangelsdorf, & Tontonoz, 2003; Zelcer & Tontonoz, 2006).”
BackgroundLiver X receptors in lipid signalling and membrane homeostasis
Wang, B., & Tontonoz, P. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0037-x · Cited by 722 · cited 1×
“Furthermore, mice models in which LXRs had been activated or deleted displayed phenotypes that have been linked to alterations in cholesterol and fatty acid homeostasis (Wang & Tontonoz, 2018).”
BackgroundGhisletti, S., Huang, W., Ogawa, S., Pascual, G., Lin, M.-E., Willson, T. M., Rosenfeld, M. G., & Glass, C. K. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.11.022 · Cited by 561 · cited 2×
“Thus, impairing co-repressor clearance decreases pro-inflammatory gene expression and finally the inflammatory signal (Ghisletti et al., 2007; Venteclef et al., 2010).”
BackgroundLXR/ApoE Activation Restricts Innate Immune Suppression in Cancer
Tavazoie, M. F., Pollack, I., Tanqueco, R., Ostendorf, B. N., Reis, B. S., Gonsalves, F. C., Kurth, I., Andreu-Agullo, C., Derbyshire, M. L., Posada, J., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.026 · Cited by 476 · cited 3×
“growth and metastasis in a wide spectrum of cancer types including colon, lung, ovarian, renal, triple-negative breast cancer, cholangiocarcinoma, glioblastoma, melanoma, and Ewing's sarcoma (Mita et al., 2018; Tavazoie et al., 2018).”
BackgroundOishi, Y., Spann, N. J., Link, V. M., Muse, E. D., Strid, T., Edillor, C., Kolar, M. J., Matsuzaka, T., Hayakawa, S., Tao, J., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.11.009 · Cited by 342 · cited 1×
“Finally, the ATPbinding cassette transporter ABCA1 was identified as the key mediator of this process (Ito et al., 2015; Oishi et al., 2017; Westerterp et al., 2013).”
BackgroundIto, A., Hong, C., Rong, X., Zhu, X., Tarling, E. J., Hedde, P. N., Gratton, E., Parks, J., & Tontonoz, P. (2015) · eLife · doi:10.7554/elife.08009 · Cited by 281 · cited 2×
“Finally, the ATPbinding cassette transporter ABCA1 was identified as the key mediator of this process (Ito et al., 2015; Oishi et al., 2017; Westerterp et al., 2013).”
BackgroundKoldamova, R. P., Lefterov, I. M., Staufenbiel, M., Wolfe, D., Huang, S., Glorioso, J. C., Walter, M., Roth, M. G., & Lazo, J. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411420200 · Cited by 279
Uhlenhaut, N. H., Barish, G. D., Yu, R. T., Downes, M., Karunasiri, M., Liddle, C., Schwalie, P., Hübner, N., & Evans, R. M. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.10.013 · Cited by 265 · cited 2×
“Similar to the glucocorticoid receptor controlling the immune response (Uhlenhaut et al., 2013), Thomas et al. (2018) pointed out that direct anti-inflammatory response is under the control of LXR cis-repression mechanism.”
BackgroundKirchgessner, T. G., Sleph, P., Ostrowski, J., Lupisella, J., Ryan, C. S., Liu, X., Fernando, G., Grimm, D., Shipkova, P., Zhang, R., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.016 · Cited by 172
Dendrogenin A drives LXR to trigger lethal autophagy in cancers
Segala, G., David, M., de Medina, P., Poirot, M. C., Serhan, N., Vergez, F., Mougel, A., Saland, E., Carayon, K., Leignadier, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01948-9 · Cited by 125
Self-citationStructure of the retinoid X receptor α-liver X receptor β (RXRα-LXRβ) heterodimer on DNA
Lou, X., Toresson, G., Benod, C., Suh, J. H., Philips, K. J., Webb, P., & Gustafsson, J.-A. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2778 · Cited by 105
The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
Griffett, K., Welch, R. D., Flaveny, C. A., Kolar, G. R., Neuschwander-Tetri, B. A., & Burris, T. P. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.01.009 · Cited by 95
Ma, L., Dong, F., Zaid, M., Kumar, A., & Zha, X. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.413245 · Cited by 68
Huang, P., Kaluba, B., Jiang, X.-L., Chang, S., Tang, X.-F., Mao, L.-F., Zhang, Z.-P., & Huang, F.-Z. (2018) · BioMed Research International · doi:10.1155/2018/8071093 · Cited by 44
Cited by
Gui, Y., Zheng, H., & Cao, R. Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.845942 · Cited by 258
Remembering your A, B, C's: Alzheimer's disease and ABCA1
Lewandowski, C. T., Laham, M. S., & Thatcher, G. R. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.011 · Cited by 76
Ma, L., Vidana Gamage, H. E., Tiwari, S., Han, C., Henn, M. A., Krawczynska, N., Dibaeinia, P., Koelwyn, G. J., Das Gupta, A., Bautista Rivas, R. O., et al. (2022) · Endocrinology · doi:10.1210/endocr/bqac072 · Cited by 21
Liver X receptors: From pharmacology to nanoparticle-based drug delivery
Hua, X., & Wei, X. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175953 · Cited by 14
Metadata
- Authors
- Buñay, J., Fouache, A., Trousson, A., de Joussineau, C., Bouchareb, E., Zhu, Z., Kocer, A., Morel, L., Baron, S., & Lobaccaro, J. A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2020-12-07
- Volume
- 178
- Issue
- 16
- Pages
- 3277-3293
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W3093526871
- Cited by
- 48
- References
- 18
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.